Event details
Collaboration to deliver NHS Long Term Plan goals on CVD and Population Health Management
A novel injectable treatment for people at risk of cardiovascular disease is being made available to patients more quickly, thanks to a three-way agreement between NHS England and NHS Improvement, the AHSN Network and the pharmaceutical company, Novartis.
Inclisiran is the first of a new type of cholesterol-lowering therapy, which uses RNA interference (RNAi) to boost the liver’s ability to remove harmful cholesterol from the blood. It can be given to people with high cholesterol who have already had a previous cardiovascular event to reduce the chances of them having another.
This webinar will introduce this innovative injectable therapy, explore it’s its place on the treatment pathway, and how it can support both the NHS Long Term Plan dual ambitions of reducing cardiovascular disease and through Population Health Management.